COMPARISON OF MASS-SPECTROMETRY AND RADIOIMMUNOASSAY TO MEASURE MEDROXYPROGESTERONE ACETATE IN PATIENTS WITH ENDOMETRIAL CANCER

被引：6

作者：

KARKKAINEN, J

VESTERINEN, E

STENMAN, UH

ADLERCREUTZ, H

NIEMINEN, U

WIDHOLM, O

机构：

[1] UNIV HELSINKI,CENT HOSP,DEPT GYNECOL,SF-00290 HELSINKI 29,FINLAND

[2] UNIV HELSINKI,MEILAHTI HOSP,DEPT CLIN CHEM,HELSINKI,FINLAND

来源：

EUROPEAN JOURNAL OF CANCER | 1990年 / 26卷 / 09期

基金：

芬兰科学院;

关键词：

D O I：

10.1016/0277-5379(90)90624-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Serum medroxyprogesterone acetate (MPA) was measured by radioimmunoassay (RIA) and gas chromatography-mass spectrometry (GC-MS) in patients with endometrial cancer. Samples were obtained 3, 6 and 24 h after the oral administration of 100 or 200 mg MPA once a day. The levels obtained by GC-MS were lower (median 16-29%) than those obtained by RIA, which is probably attributable to the presence of metabolites interfering with the RIA. Two commercial MPA formulations gave different MPA serum levels by both RIA and GC-MS. The levels obtained by GC-MS were so low that frequently only partial saturation of the endometrial progesterone receptor may be achieved which may explain why high oral doses are needed to produce optimum therapeutic response.

引用

页码：975 / 977

页数：3